Announced positive initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pLGG, with a 64% overall response rate (ORR) and 91% CBR in the 22 RANO-evaluable patients.

Initiated a pivotal Phase 3 clinical trial (FIREFLY-2/LOGGIC) evaluating tovorafenib as a front-line therapy for patients newly diagnosed with pLGG.

Raised gross proceeds of $172.5 million through an upsized public offering, extending the Company’s cash runway into 2025.

Anticipates releasing topline results for the full FIREFLY-1 pivotal study population in the first quarter of 2023 and expects to submit a new drug application (NDA) to the FDA in the first half of 2023 if the data are supportive.